North America & Europe PEGylated Drugs Market will reach USD 10.5 Billion by 2024; as per a new research report.

Rising incidences of chronic ailments including cancer, multiple sclerosis in the developed economies will act as a major driver for PEGylated drugs market growth. Favorable government support along with increasing funding for research and development by major biopharmaceutical companies in the U.S. and Europe will propel industry growth.

Growing biologics sector in the developed regions will substantially influence the PEGylated drugs industry over the coming few years. Growing investment for biologics, efficient regulatory process coupled with increased efforts of industry players to develop innovative medicines and drugs are factors contributing towards market growth.

Potential safety risks such as vacuolation and hypersensitivity reactions due to uptake of pegylated drugs will impede market growth. Drug recalls owing to adverse side effects of drugs is further expected to hamper revenue size.

Cancer dominated the industry owing to the high prevalence of the disease across North America and European region. Increasing government spending for cancer research along with availability of pegylated drugs such as Neulasta and Oncaspar offering numerous benefits for effective treatment of cancer will stimulate market growth in the future.

Multiple sclerosis will witness considerable growth over the coming years. This growth is attributable to increasing usage of Plegridy, a peginterferon beta-1 drug used for the treatment of relapsing multiple sclerosis.

Colony stimulating factors held the largest revenue share in 2017 due to increasing adoption of granulocyte CSF called pegfilgrastin. Benefits offered by such molecules such as reducing the risk of neutropenia and infections caused by bone marrow transplantation or chemotherapy will boost its market growth.

U.S. was dominating the PEGylated drugs industry due to the presence of large patient pool suffering from chronic disorders along with growing biologics sector in the country. Increasing investments for R&D by pharmaceutical players along with availability of numerous approved pegylated drugs will further contribute towards market growth.

Germany pegylated drugs market will experience considerable growth due to growing prevalence of chronic diseases along with presence of well-established and local players developing PEGylated drugs in the country.

Some of the notable industry players are Shire Group, UCB, Merck, AstraZeneca, Amgen, Sigma Tau, Biogen, Pfizer and Roche. Growing focus of major industry players on research activities for the development of effective therapeutics along with the presence of considerable number of products in their pipeline will escalate market growth in the coming years.